Publications by authors named "Egbert Smit"

Claim this Profile
F
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Pasi A Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, Egbert Smit

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
Hanieh Abedian Kalkhoran, Marjon V Verschueren, Bas J M Peters, Ewoudt M W van de Garde, Egbert F Smit

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
Mariana Brandão, Elena Prisciandaro, Eleni Xenophontos, Alessio Mariolo, Amir H Sadeghi, Egbert Smit

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Pasi A Jänne, David Planchard, Koichi Goto, Egbert F Smit, Adrianus Johannes de Langen

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?
Daphne van der Geest, Alex van Vliet, Daniel S Peeper, John B A G Haanen, Egbert F Smit

J Immunother Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper, Egbert F Smit

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.
Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, Makoto Nishio, Melissa L Johnson, Egbert F Smit

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment.
J W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, Ferry Lalezari, Daan van den Broek, Egbert F Smit

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib for KRAS mutated advanced non-small-cell lung cancer.
Egbert F Smit, Anne-Marie C Dingemans

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, Hanieh Abedian Kalkhoran, Egbert F Smit

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, Hanieh Abedian Kalkhoran, Egbert F Smit

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.
Zhenhao Qi, Thomas Ha, Wenqin Feng, Maha Karnoub, Kaline Pereira, Egbert F Smit

Arch Pathol Lab Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zongertinib in Previously Treated -Mutant Non-Small-Cell Lung Cancer.
John V Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert F Smit

N Engl J Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials.
Sophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, Adrianus J de Langen, Egbert F Smit

Nat Rev Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.
Mitchell Emmers, Marij J P Welters, Michelle V Dietz, Saskia J Santegoets, Sanne Boekesteijn, Egbert F Smit

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials.
Barend J Sikkema, Sara J Baart, Marthe S Paats, Egbert F Smit, Annemie M W J Schols

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring exon 14 skipping treated with systemic therapy.
Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazières, Alexis B Cortot, Egbert F Smit

J Comp Eff Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.
Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, Sara Wienke, Maha Karnoub, Egbert F Smit

J Mol Diagn· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.
Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran, Egbert F Smit

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Egbert F Smit

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, Noemi Reguart, Pierre-Jean Souquet, Egbert F Smit

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Egbert F Smit

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Suzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P Nicolet, Marleen M van Loenen, Egbert F Smit

Oncoimmunology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis